Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

摘要

Introduction: Despite a clinically relevant, statistically significant survival benefit with nab -paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent gemcitabine for metastatic pancreatic cancer (mPC), little is known regarding their real-world effectiveness. We analyzed patients with mPC using a nationally representative electronic medical records database to address this unmet need. Methods: This retrospective analysis of the Navigating Cancer database compared outcomes among patients who received first-line nab -paclitaxel plus gemcitabine, FOLFIRINOX, or gemcitabine for mPC. Effectiveness, safety, and supportive care use were examined. nab -Paclitaxel plus gemcitabine was the reference for statistical comparisons. Results: Baseline characteristics were similar except age (oldest patients were in the gemcitabine cohort followed by nab -paclitaxel plus gemcitabine, then FOLFIRINOX). Patients receiving nab -paclitaxel plus gemcitabine (n=122) demonstrated similar time to treatment discontinuation (TTD; median, 3.4 vs 3.8 months; P =0.947) and database persistence (DP; median, 8.6 vs 8.6 months; P =0.534) vs FOLFIRINOX (n=80); however, TTD (median, 3.4 vs 2.2 months; P <0.001) and DP (median, 8.6 vs 5.3 months; P =0.030) were significantly longer with nab -paclitaxel plus gemcitabine vs gemcitabine (n=46). There were more any-grade adverse events with FOLFIRINOX or gemcitabine vs nab -paclitaxel plus gemcitabine (95% or 89% vs 84%, respectively). Conclusion: This real-world analysis confirms the phase III MPACT trial findings and demonstrates that nab -paclitaxel plus gemcitabine has effectiveness similar to that of FOLFIRINOX but greater tolerability for treating mPC despite younger patients being in the FOLFIRINOX cohort. These findings support nab -paclitaxel plus gemcitabine as an appropriate first-line treatment option for patients with mPC.